Clinical Trial Details
| Trial ID: | L2404 |
| Source ID: | NCT03689374 |
| Associated Drug: | Semaglutide |
| Title: | A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes |
| Acronym: | SUSTAIN 11 |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT03689374/results |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: Semaglutide|DRUG: Insulin aspart|DRUG: Insulin glargine U100 |
| Outcome Measures: | Primary: Change From Baseline in Glycated Haemoglobin (HbA1c), Change from baseline in HbA1c at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52 | Secondary: Time to First Event Adjudication Committee (EAC)-Confirmed Severe Hypoglycaemic Episode American Diabetes Association (ADA) From Randomization up to Week 52, First event per 100 years of exposure time for first EAC confirmed severe hypoglycaemic episodes from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with plasma glucose (PG) less than or equal to (\<=) 3.9 millimoles per liter (mmol/L) (70 milligrams per deciliter (mg/dL)). EAC confirmed-severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., From randomization (week 0) up to week 52|Time to First Event Adjudication Committee-confirmed Severe Hypoglycaemic Episode (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening Randomization up to Week 52, First event per 100 years of exposure time for first EAC confirmed severe hypoglycaemic episodes requiring hospitalization, documented medical help, or is life threatening from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \<=3.9 mmol/L (70 mg/dL). EAC confirmed-severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., From randomization (week 0) up to week 52|Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) From Randomization to Week 52, Number of EAC-confirmed severe hypoglycaemic episodes from randomization (week 0) up to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \<=3.9 mmol/L (70 mg/dL). EAC confirmed-severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., From randomization (week 0) to week 52|Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose (BG) Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose Less Than (<) 3.1 mmol/L (56 mg/dL)) From Randomization to Week 52, Number of EAC-confirmed severe or BG confirmed, symptomatic hypoglycaemic episodes (PG \<3.1 mmol/L (56 mg/dL)) from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \<=3.9 mmol/L (70 mg/dL). Severe or BG confirmed symptomatic hypoglycaemia was an episode, that was BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., From randomization (week 0) to week 52|Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose <= 3.9 mmol/L (70 mg/dL)) From Randomization to Week 52, Number of EAC-confirmed severe or BG confirmed, symptomatic hypoglycaemic episodes (PG \<=3.9 mmol/L (70 mg/dL)) from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \<=3.9 mmol/L (70 mg/dL). Severe or BG confirmed symptomatic hypoglycaemia was an episode during which symptoms of hypoglycaemia were not accompanied by a PG determination but that was presumably caused by a PG concentration \<= 3.9 mmol/L (70 mg/dL). Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., From randomization (week 0) to week 52|Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening From Randomization to Week 52, Number of EAC-confirmed severe hypoglycaemic episodes requiring hospitalization, documented medical help, or is life-threatening from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \<=3.9 mmol/L (70 mg/dL). Severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., From randomization (week 0) to week 52|Number of Event Adjudication Committee-confirmed Severe (ADA) or Clinically Significant Hypoglycaemic Episodes (Plasma Glucose < 3.0 mmol/L (54 mg/dL)) From Randomization to Week 52, Number of EAC-confirmed severe or clinically significant hypoglycaemic episodes (plasma glucose \< 3.0 mmol/L (54 mg/dL)) from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \<=3.9 mmol/L (70 mg/dL). Severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Hypoglycaemic episode with plasma glucose \< 3.0 mmol/L (54 mg/dL)) was considered as clinically significant. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., From randomization (week 0) to week 52|Daily Basal Insulin Dose at Week 52, Daily basal insulin dose at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., At week 52|Total Daily Insulin Dose at Week 52, Total daily insulin dose at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., At week 52|Change From Baseline to Week 52 in Body Weight (Kilogram (kg)), Change from baseline in body weight at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Fasting Plasma Glucose (FPG), Change from baseline in FPG at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in 7-point Self-measured Plasma Glucose Profile (SMPG ): Mean 7-point Profile (7-PP), Change from baseline in 7-point self-measured plasma glucose profile: mean 7-PP at week 52 is presented. All participants were instructed to perform 7-point SMPG profiles before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before main evening meal (dinner), 90 minutes after the start of main evening meal (dinner) and at bedtime. The measurements were to be performed before any injection of bolus insulin and just before the start of the meal (breakfast, lunch or main evening meal), and values measured before breakfast were performed in a fasting condition. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in 7-point Self-measured Plasma Glucose Profile: Mean Post-prandial Increment (Over All Meals), Change from baseline in 7-point SMPG profile: mean post-prandial increment (over all meals) at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Body Mass Index (BMI), Change from baseline in BMI at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Waist Circumference, Change from baseline in waist circumference at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Body Weight (Percentage): Ratio to Baseline, Change from baseline in body weight (measured in percentage) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Fasting Blood Lipids: Total Cholesterol (Ratio to Baseline), Change from baseline in total cholesterol (measured in mmol/L) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Fasting Blood Lipids: Low-density Lipoprotein (LDL) Cholesterol (Ratio to Baseline), Change from baseline in LDL cholesterol (measured in mmol/L) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Fasting Blood Lipids: High-density Lipoprotein (HDL) Cholesterol (Ratio to Baseline), Change from baseline in HDL cholesterol (measured in mmol/L) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Fasting Blood Lipids: Triglycerides (Ratio to Baseline), Change from baseline in triglycerides (measured in mmol/L) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Systolic and Diastolic Blood Pressure, Change from baseline in systolic and diastolic blood pressure at week 52 are presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Pulse Rate, Change from baseline in pulse rate at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in 36-item Short Form Health Survey Version 2 (SF-36v2): Total Summary Scores (Physical Component and Mental Component) and Scores From the 8 Domains, SF-36v2 is 36-item patient-reported survey of patient health to measure participant's overall health-related quality of life (HRQoL). It has 36 items: 8 domains of physical, mental health status (physical functioning, role physical health (range:21.23-57.16), bodily pain (range: 21.68-62.00), general health (range: 18.95-66.50), vitality (range: 22.89-70.42), social functioning (range: 17.23-57.34), role emotional problem (range: 14.39-56.17) and mental health (range: 11.63-63.95)) and 2 total summary scores: physical components summary (range: 7.32-70.14) and mental components summary (range: 5.79-69.91) calculated from domain scores. All 10 scores range from 5.79-70.42 . Higher scores indicated a better health state. Change from baseline in SF-36v2, 2 summary and 8 domains scores at week 52 is presented. Data is reported for 'on-treatment' observation period: from date of first dose of trial product (week 0) to last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52|Change From Baseline to Week 52 in Diabetes Quality of Life Clinical Trial Questionnaire (DQLCTQ-R): Scores From the 8 Domains, The DQLCTQ-R questionnaire was used to assess participants' HRQoL. The DQLCTQ-R questionnaire contains 57 items and measures and provide scores for the 8 domains (physical function, energy or fatigue, health distress, mental health, satisfaction, treatment satisfaction, treatment flexibility and frequency of symptoms). The 8 domain scores related to DQLCTQ-R are measured on a scale from 0-100. For all scores, higher values indicated better health status. Change from baseline in DQLCTQ-R 8 domain scores at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52)., Baseline (week 0), week 52 |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 2274 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2018-10-01 |
| Completion Date: | 2021-02-22 |
| Results First Posted: | 2022-05-04 |
| Last Update Posted: | 2022-11-14 |
| Locations: | Novo Nordisk Investigational Site, Banja Luka, 78000, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Sarajevo, 71000, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Tuzla, 75000, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Burgas, 8000, Bulgaria|Novo Nordisk Investigational Site, Byala, 7100, Bulgaria|Novo Nordisk Investigational Site, Dimitrovgrad, 6400, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, 4002, Bulgaria|Novo Nordisk Investigational Site, Ruse, 7000, Bulgaria|Novo Nordisk Investigational Site, Sofia, 1632, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, 6000, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, 6001, Bulgaria|Novo Nordisk Investigational Site, Varna, 9010, Bulgaria|Novo Nordisk Investigational Site, Karlovac, 47000, Croatia|Novo Nordisk Investigational Site, Osijek, 31 000, Croatia|Novo Nordisk Investigational Site, Pula, 52100, Croatia|Novo Nordisk Investigational Site, Rijeka, 51 000, Croatia|Novo Nordisk Investigational Site, Varazdin, 42 000, Croatia|Novo Nordisk Investigational Site, Zagreb, 10 000, Croatia|Novo Nordisk Investigational Site, Beroun, 26601, Czechia|Novo Nordisk Investigational Site, Brno, 602 00, Czechia|Novo Nordisk Investigational Site, Kladno - Krocehlavy, 272 01, Czechia|Novo Nordisk Investigational Site, Mlada Boleslav, 293 50, Czechia|Novo Nordisk Investigational Site, Nachod, 54701, Czechia|Novo Nordisk Investigational Site, Olomouc, 77900, Czechia|Novo Nordisk Investigational Site, Plzeň, 301 00, Czechia|Novo Nordisk Investigational Site, Prostejov, 79601, Czechia|Novo Nordisk Investigational Site, Pärnu, 80018, Estonia|Novo Nordisk Investigational Site, Tallinn, 10138, Estonia|Novo Nordisk Investigational Site, Tallinn, 10617, Estonia|Novo Nordisk Investigational Site, Tallinn, 13419, Estonia|Novo Nordisk Investigational Site, Viljandi, 71024, Estonia|Novo Nordisk Investigational Site, Bad Kreuznach, 55545, Germany|Novo Nordisk Investigational Site, Bad Mergentheim, 97980, Germany|Novo Nordisk Investigational Site, Berlin, 10437, Germany|Novo Nordisk Investigational Site, Berlin, 10629, Germany|Novo Nordisk Investigational Site, Berlin, 10787, Germany|Novo Nordisk Investigational Site, Berlin, 13597, Germany|Novo Nordisk Investigational Site, Eisenach, 99817, Germany|Novo Nordisk Investigational Site, Essen, 45136, Germany|Novo Nordisk Investigational Site, Essen, 45355, Germany|Novo Nordisk Investigational Site, Essen, 45359, Germany|Novo Nordisk Investigational Site, Esslingen, 73728, Germany|Novo Nordisk Investigational Site, Falkensee, 14612, Germany|Novo Nordisk Investigational Site, Friedrichsthal, 66299, Germany|Novo Nordisk Investigational Site, Hamburg, 22041, Germany|Novo Nordisk Investigational Site, Hamburg, 22607, Germany|Novo Nordisk Investigational Site, Hohenmölsen, 06679, Germany|Novo Nordisk Investigational Site, Jerichow, 39319, Germany|Novo Nordisk Investigational Site, Kiel Kronshagen, 24119, Germany|Novo Nordisk Investigational Site, Leipzig, 04249, Germany|Novo Nordisk Investigational Site, Münster, 48145, Germany|Novo Nordisk Investigational Site, Münster, 48153, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, 23758, Germany|Novo Nordisk Investigational Site, Pohlheim, 35415, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, 66780, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, 66386, Germany|Novo Nordisk Investigational Site, Schwabenheim, 55270, Germany|Novo Nordisk Investigational Site, Schweinfurt, 97421, Germany|Novo Nordisk Investigational Site, Stuhr, 28816, Germany|Novo Nordisk Investigational Site, Stuttgart, 70199, Germany|Novo Nordisk Investigational Site, Stuttgart, 70378, Germany|Novo Nordisk Investigational Site, Villingen-Schwenningen, 78048, Germany|Novo Nordisk Investigational Site, Alexandroupolis, GR-68100, Greece|Novo Nordisk Investigational Site, Athens, 115 21, Greece|Novo Nordisk Investigational Site, Athens, 115 25, Greece|Novo Nordisk Investigational Site, Athens, 11522, Greece|Novo Nordisk Investigational Site, Athens, GR-115 27, Greece|Novo Nordisk Investigational Site, Athens, GR-11521, Greece|Novo Nordisk Investigational Site, Athens, GR-11526, Greece|Novo Nordisk Investigational Site, Athens, GR-11527, Greece|Novo Nordisk Investigational Site, Larissa, GR-41110, Greece|Novo Nordisk Investigational Site, Piraeus, GR-18536, Greece|Novo Nordisk Investigational Site, Thessaloniki, GR-54642, Greece|Novo Nordisk Investigational Site, Thessaloniki, GR-54643, Greece|Novo Nordisk Investigational Site, Thessaloniki, GR-57001, Greece|Novo Nordisk Investigational Site, Thessaloniki, GR-57010, Greece|Novo Nordisk Investigational Site, Budapest, 1033, Hungary|Novo Nordisk Investigational Site, Budapest, 1042, Hungary|Novo Nordisk Investigational Site, Budapest, 1089, Hungary|Novo Nordisk Investigational Site, Gyula, 5700, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, 8800, Hungary|Novo Nordisk Investigational Site, Pécs, 7623, Hungary|Novo Nordisk Investigational Site, Salgótarján, 3100, Hungary|Novo Nordisk Investigational Site, Szeged, H-6725, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, 8900, Hungary|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, 500072, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, 560034, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, 560092, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, 452010, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, 400012, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, 400058, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, 440010, India|Novo Nordisk Investigational Site, Pune, Maharashtra, 411040, India|Novo Nordisk Investigational Site, Delhi, New Delhi, 110002, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, 110029, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, 751005, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, 751019, India|Novo Nordisk Investigational Site, Chandigarh, Punjab, 160012, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, 141001, India|Novo Nordisk Investigational Site, Mohali, Punjab, 160062, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, 302006, India|Novo Nordisk Investigational Site, Madurai, Tamil Nadu, 625 020, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, 500003, India|Novo Nordisk Investigational Site, Hyderbad, Telengana, 500 012, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, 700054, India|Novo Nordisk Investigational Site, New Delhi, 110001, India|Novo Nordisk Investigational Site, Jelgava, LV-3001, Latvia|Novo Nordisk Investigational Site, Ogre, LV-5001, Latvia|Novo Nordisk Investigational Site, Riga, LV-1002, Latvia|Novo Nordisk Investigational Site, Riga, LV-1024, Latvia|Novo Nordisk Investigational Site, Sigulda, LV-2150, Latvia|Novo Nordisk Investigational Site, Talsi, LV-3201, Latvia|Novo Nordisk Investigational Site, Kaunas, 48259, Lithuania|Novo Nordisk Investigational Site, Kaunas, 49449, Lithuania|Novo Nordisk Investigational Site, Kaunas, 50009, Lithuania|Novo Nordisk Investigational Site, Panevezys, 37355, Lithuania|Novo Nordisk Investigational Site, Vilnius, 04318, Lithuania|Novo Nordisk Investigational Site, Vilnius, 08661, Lithuania|Novo Nordisk Investigational Site, Skopje, 1000, North Macedonia|Novo Nordisk Investigational Site, Bialystok, 15-276, Poland|Novo Nordisk Investigational Site, Bialystok, 15-351, Poland|Novo Nordisk Investigational Site, Bialystok, 15-704, Poland|Novo Nordisk Investigational Site, Gorzow Wielkopolski, 66-400, Poland|Novo Nordisk Investigational Site, Lodz, 94-074 LODZ, Poland|Novo Nordisk Investigational Site, Lublin, 20-044, Poland|Novo Nordisk Investigational Site, Lublin, 20-090, Poland|Novo Nordisk Investigational Site, Lublin, 20-538, Poland|Novo Nordisk Investigational Site, Poznan, 60-589, Poland|Novo Nordisk Investigational Site, Poznan, 61-251, Poland|Novo Nordisk Investigational Site, Poznan, 61-853, Poland|Novo Nordisk Investigational Site, Pulawy, 24-100, Poland|Novo Nordisk Investigational Site, Ruda Slaska, 41-709, Poland|Novo Nordisk Investigational Site, Siedlce, 08-110, Poland|Novo Nordisk Investigational Site, Skorzewo, 60-185, Poland|Novo Nordisk Investigational Site, Warsaw, 00-465, Poland|Novo Nordisk Investigational Site, Wierzchoslawice, 33-122, Poland|Novo Nordisk Investigational Site, Wroclaw, 50-127, Poland|Novo Nordisk Investigational Site, Wroclaw, 51-685, Poland|Novo Nordisk Investigational Site, Zabrze, 41-800, Poland|Novo Nordisk Investigational Site, Almada, 2805-267, Portugal|Novo Nordisk Investigational Site, Braga, 4710-243, Portugal|Novo Nordisk Investigational Site, Coimbra, 3000-561, Portugal|Novo Nordisk Investigational Site, Lisboa, 1250-230, Portugal|Novo Nordisk Investigational Site, Loures, 2674-514, Portugal|Novo Nordisk Investigational Site, Porto, 4200-319, Portugal|Novo Nordisk Investigational Site, Setubal, 2910-446, Portugal|Novo Nordisk Investigational Site, Cluj Napoca, Cluj, 400006, Romania|Novo Nordisk Investigational Site, Targoviste, Dambovita, 130086, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, 540098, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, 100018, Romania|Novo Nordisk Investigational Site, Brasov, 500101, Romania|Novo Nordisk Investigational Site, Brasov, 500283, Romania|Novo Nordisk Investigational Site, Galati, 800578, Romania|Novo Nordisk Investigational Site, Belgrade, 11000, Serbia|Novo Nordisk Investigational Site, Belgrade, 11080, Serbia|Novo Nordisk Investigational Site, Kragujevac, 34000, Serbia|Novo Nordisk Investigational Site, Nis, 18000, Serbia|Novo Nordisk Investigational Site, Novi Sad, 21000, Serbia|Novo Nordisk Investigational Site, Zajecar, 19000, Serbia|Novo Nordisk Investigational Site, Bardejov, 08501, Slovakia|Novo Nordisk Investigational Site, Bratislava, 811 08, Slovakia|Novo Nordisk Investigational Site, Bratislava, 81108, Slovakia|Novo Nordisk Investigational Site, Bratislava, 82606, Slovakia|Novo Nordisk Investigational Site, Dolny Kubin, 02601, Slovakia|Novo Nordisk Investigational Site, Levice, 93401, Slovakia|Novo Nordisk Investigational Site, Lubochna, 03491, Slovakia|Novo Nordisk Investigational Site, Martin, 03601, Slovakia|Novo Nordisk Investigational Site, Presov, 080 01, Slovakia|Novo Nordisk Investigational Site, Prievidza, 97101, Slovakia|Novo Nordisk Investigational Site, Sabinov, 08301, Slovakia|Novo Nordisk Investigational Site, Brezice, 8250, Slovenia|Novo Nordisk Investigational Site, Jesenice, SI-4270, Slovenia|Novo Nordisk Investigational Site, Koper, SI-6000, Slovenia|Novo Nordisk Investigational Site, Murska Sobota, SI-9000, Slovenia|Novo Nordisk Investigational Site, Nova Gorica, SI-5000, Slovenia|Novo Nordisk Investigational Site, Nova Gorica, SI-5290, Slovenia|Novo Nordisk Investigational Site, Benoni, Gauteng, 1501, South Africa|Novo Nordisk Investigational Site, Cosmo City, Gauteng, 2188, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, 1818, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, 2198, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, 1827, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, 0002, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, 0122, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, 4092, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, 4450, South Africa|Novo Nordisk Investigational Site, Umkomaas, KwaZulu-Natal, 4170, South Africa|Novo Nordisk Investigational Site, Almeria, 04009, Spain|Novo Nordisk Investigational Site, Antequera, 29200, Spain|Novo Nordisk Investigational Site, Córdoba, 14004, Spain|Novo Nordisk Investigational Site, Fuenlabrada - Madrid, 28942, Spain|Novo Nordisk Investigational Site, Madrid, 28006, Spain|Novo Nordisk Investigational Site, Málaga, 29006, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, 07010, Spain|Novo Nordisk Investigational Site, Segovia, 40002, Spain|Novo Nordisk Investigational Site, Sevilla, 41003, Spain|Novo Nordisk Investigational Site, Adana, 01130, Turkey|Novo Nordisk Investigational Site, Ankara, 06500, Turkey|Novo Nordisk Investigational Site, Antalya, 07058, Turkey|Novo Nordisk Investigational Site, Denizli, 20070, Turkey|Novo Nordisk Investigational Site, Erzurum, 25240, Turkey|Novo Nordisk Investigational Site, Istanbul, 34303, Turkey|Novo Nordisk Investigational Site, Istanbul, 34390, Turkey|Novo Nordisk Investigational Site, Istanbul, 34400, Turkey|Novo Nordisk Investigational Site, Istanbul, 34722, Turkey|Novo Nordisk Investigational Site, Istanbul, 34760, Turkey|Novo Nordisk Investigational Site, Istanbul, 34899, Turkey|Novo Nordisk Investigational Site, Izmir, 35100, Turkey|Novo Nordisk Investigational Site, Izmir, 35340, Turkey|Novo Nordisk Investigational Site, Trabzon, 61080, Turkey |
| URL: | https://clinicaltrials.gov/show/NCT03689374 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|